Fortress Biotech Amends SEC Filing for Checkpoint Therapeutics

TL;DR

Fortress Biotech just updated its 13D filing for Checkpoint Therapeutics. Watch for ownership changes.

AI Summary

Fortress Biotech, Inc. filed an amendment (No. 6) to its Schedule 13D on March 22, 2024, regarding its holdings in Checkpoint Therapeutics, Inc. The filing indicates changes in beneficial ownership, though specific new percentages or dollar amounts are not detailed in this excerpt. Fortress Biotech, Inc. is listed as the filer, with Lindsay A. Rosenwald, M.D. as a contact.

Why It Matters

This amendment signals potential shifts in the ownership structure or strategy of Fortress Biotech concerning its investment in Checkpoint Therapeutics, which could impact market perception and stock performance for both companies.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings can indicate significant changes in a major shareholder's stake or intentions, potentially leading to volatility.

Key Players & Entities

• Fortress Biotech, Inc. (company) — Filer of the Schedule 13D/A
• Checkpoint Therapeutics, Inc. (company) — Subject company of the Schedule 13D/A
• Lindsay A. Rosenwald, M.D. (person) — Contact person for Fortress Biotech, Inc.

FAQ

Key Financial Figures

• $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.00
• $1.29 — rrants, which have an exercise price of $1.29 per share, are exercisable until July 1

Filing Documents

• tm249605-1_sc13da.htm (SC 13D/A) — 48KB
• 0001104659-24-037987.txt ( ) — 50KB

and the Warrants in Footnote 1 above

Item 3 and the Warrants in Footnote 1 above. Item 7. Materials to be Filed as Exhibits. Exhibit 7.01 Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., dated March 3, 2015, incorporated by reference to Exhibit 3.1 to the Form 10-12G filed by the Issuer with the SEC on July 11, 2016 (File No. 000-55506).* Exhibit 7.02 Amendment to the Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., dated June 14, 2018, incorporated by reference to Exhibit 10.1 to the Form 10-Q filed by the Issuer with the SEC on August 7, 2018 (File No. 001-38128).* Exhibit 7.03 Form of Amended and Restated Common Stock Warrant issued by Reporting Person to Dr. Rosenwald and Mr. Weiss for Issuer common stock, incorporated by reference to Exhibit 7.01 to the Schedule 13D filed by the Reporting Person with the SEC on May 26, 2017 (File No. 005-89990).* Exhibit 7.04 Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Checkpoint Therapeutics, Inc. dated July 11, 2016 and effective as of March 17, 2015, incorporated by reference to Exhibit 10.2 to the Form 10-12G filed by the Issuer with the SEC on July 11, 2016 (File No. 000-55506).* Exhibit 7.05 First Amendment to the Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Checkpoint Therapeutics, Inc. dated October 5, 2017, incorporated by reference to Exhibit 10.2.1 to the Form 10-K filed by the Issuer with the SEC on March 18, 2019 (File No. 001-38128).* * Previously Filed. CUSIP No. 162828 206 Page 7 of 7 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: March 22, 2024 FORTRESS BIOTECH, INC. By: /s/ Lindsay A. Rosenwald Name: Lindsay A. Rosenwald, M.D. Title: Chairman, President and Chief Executive Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR